Related Experiment Video
Updated: Aug 28, 2025

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Cefadroxil Use for Musculoskeletal Infections in an Academic Pediatric Hospital
Erin Weslander1, Holly Thomas2, Ralph Jeune3
1Department of Pharmacy, Northwestern Memorial Hospital, USA.
Abstract:
Forty-nine of 52 (94.2%) children with musculoskeletal infection (MSKI) were successfully treated with cefadroxil dosed at 30 mg/kg/day over a 10-year time period. Two failures were associated with poor medication adherence. Our study suggests that treatment of MSKI with cefadroxil offers acceptable outcomes. Confirmation through clinical trials is appropriate.
Insights
Cefadroxil effectively treated most pediatric musculoskeletal infections (MSKI) in a 10-year study. This antibiotic shows promise for MSKI management, warranting further clinical trials.
Area of Science:
- Pediatric infectious diseases
- Pharmacological treatment of bone and joint infections
Background:
- Musculoskeletal infections (MSKI) in children require effective antibiotic therapy.
- Assessing treatment outcomes for pediatric MSKI is crucial for clinical practice.
Purpose of the Study:
- To evaluate the efficacy and outcomes of cefadroxil in treating pediatric musculoskeletal infections.
- To determine the success rate of cefadroxil in a real-world clinical setting over a decade.
Main Methods:
- Retrospective analysis of pediatric patients diagnosed with MSKI over a 10-year period.
- Treatment administered included cefadroxil at a dosage of 30 mg/kg/day.
- Outcomes were assessed based on successful treatment and treatment failures.
Main Results:
- A high success rate of 94.2% (49 out of 52 children) was observed with cefadroxil treatment.
- Treatment failures in two cases were attributed to poor medication adherence.
- Cefadroxil demonstrated acceptable outcomes for the majority of pediatric MSKI cases.
Conclusions:
- Cefadroxil is an effective treatment option for pediatric musculoskeletal infections.
- Medication adherence is a critical factor for successful treatment outcomes in pediatric MSKI.
- Further confirmation through prospective clinical trials is recommended to validate these findings.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Tonsillitis II: Management
Urine Studies II: Urine Culture and Sensitivity Test
Acute Pyelonephritis I: Introduction
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:

